Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

Tazemetostat Shows Antitumor Activity in INI1-Negative Pediatric Tumors

May 4th 2018

Tazemetostat demonstrated promising antitumor activity in pediatric patients with INI1-negative solid tumors.

Dr. Chi on Study of Tazemetostat in Children With INI1-Negative Tumors

May 4th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of Pediatrics, Harvard Medical School, discusses a phase I multicenter trial of tazemetostat in children with INI1-negative tumors.

Dr. Bailey Discusses Key Molecular Pathways in Bone Sarcoma

May 3rd 2018

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses key molecular pathways in pediatric bone sarcoma.

Dr. Crompton Discusses Liquid Biopsies in Pediatric Sarcoma

May 3rd 2018

Brian D. Crompton, MD, physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses the utilization of liquid biopsies in pediatric patients with sarcoma.

AYA Patients With Cancer Want to Know More About Prognosis

May 1st 2018

Adolescent and young adult patients with cancer placed a high importance on prognostic information, and obtaining that knowledge was associated with improved well-being.

FDA Halts Enrollment on Tazemetostat Trials

April 24th 2018

The FDA has halted enrollment on clinical trials of tazemetostat in patients with various solid tumors and hematologic malignancies.

Dr. Bosse on the Treatment of Neuroblastoma in Pediatric Patients

April 24th 2018

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses the treatment of pediatric patients with high-risk neuroblastoma.

Radiation Avoidable in Some Wilms Tumor Patients With Lung Metastases

April 24th 2018

A novel risk stratification and treatment approach led to enhanced clinical outcomes overall, as well as the successful omission of radiotherapy for some patients with stage IV favorable histology Wilms tumor and pulmonary metastases.

Dr. Kaplan on Treating Solid Tumors in Pediatric Patients

April 19th 2018

Rosandra N. Kaplan, MD, investigator, Pediatric Oncology Branch, Head, Tumor Microenvironment Section, National Cancer Institute, discusses the treatment of pediatric patients with solid tumors.

Expert Discusses Dramatic Larotrectinib Data in Pediatric Cancer

April 6th 2018

Ramamoorthy Nagasubramanian, MD, discusses the results of the phase I/II study of larotrectinib in pediatric patients.

Larotrectinib Exceeds 90% Response Rate in TRK+ Pediatric Cancers

April 3rd 2018

Larotrectinib induced an “unprecedented” objective response rate of 93% in patients with TRK fusion–positive solid tumors.

Larotrectinib FDA Submission Completed for TRK Fusion Cancer

March 26th 2018

A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

FDA Approves Nilotinib for Pediatric CML

March 22nd 2018

The FDA has approved nilotinib for the first- and second-line treatment of pediatric patients aged 1 year and older with Philadelphia chromosome–positive chronic myeloid leukemia in the chronic phase.

IKZF1 Deletions Predict Poor Prognosis in Pediatric ALL

March 7th 2018

IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL.

Larotrectinib Update Shows Durable Responses in TRK-positive Cancers

February 22nd 2018

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

Rhabdomyosarcoma Cell Origin Affects Treatment and Survival of Pediatric Patients

February 9th 2018

Mark E. Hatley, MD, discusses the research of endothelial progenitor cells in pediatric patients with rhabdomyosarcoma and how it can lead to thorough analyses of the tumor cells.

Childhood Cancer Increases Likelihood of Unemployment as Adult

February 2nd 2018

One out of 6 survivors of childhood cancer was unemployed, according to results from a meta-analysis of 56 studies conducted in the United States, Canada, Asia, and Europe.

Tisagenlecleucel Responses in Pediatric ALL Sustained With Longer Follow-up

February 1st 2018

At a median follow-up of 13.1 months, tisagenlecleucel (Kymriah) induced an overall remission rate of 81% in children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia.

FDA Puts Clinical Holds on Trials of BPX-501

January 31st 2018

The FDA has halted 4 US studies of BPX-501, a novel cellular immunotherapy for cancers and orphan inherited blood disorders, after 3 patients developed encephalopathy possibly related to treatment with BPX-501.

Change in Treatment Administration May Reduce Osteonecrosis in Pediatric ALL

January 26th 2018

The method of treatment administration in the JACLS ALL-97 and ALL-02 trials may have contributed to a lower incidence of osteonecrosis in Japanese children with acute lymphoblastic leukemia.